Argentina's Seismic IP Shift: The U.S.–Argentina Agreement on Reciprocal Trade and Investment Reshapes Patent Strategy for Pharma, Biotech, and Beyond

For patent practitioners managing global portfolios, particularly in the pharmaceutical, biopharmaceutical, biotechnology, and chemistry sectors, Argentina has long presented a frustrating paradox. As Latin America's third-largest economy, with significant scientific infrastructure and a tradition of advanced research, Argentina should be a natural destination for patent filings. Yet for decades, the country's absence from the Patent Cooperation Treaty (PCT), combined with a uniquely restrictive set of patentability guidelines targeting chemical, pharmaceutical and biotechnology inventions, has forced applicants into workarounds, compressed timelines, and, in many cases, abandonment of Argentine patent protection altogether.

That calculus is now poised to change dramatically.

On February 5, 2026, the United States and Argentina signed the Agreement on Reciprocal Trade and Investment (commonly referred to by its Spanish acronym, ARTI), a sweeping bilateral instrument that goes far beyond conventional trade facilitation. Embedded within its provisions is what may be the most ambitious restructuring of Argentina's intellectual property regime in modern memory: a binding commitment to accede to the PCT, repeal restrictive patentability regulations that have been in force for over a decade, join multiple additional international IP treaties, and implement stronger enforcement mechanisms, all on an aggressive timeline.

For practitioners and portfolio managers, this is not a theoretical development to monitor passively. The ARTI creates immediate strategic imperatives, from reassessing filing timelines and claim drafting approaches for pending and future Argentine applications to building Argentina into the PCT national phase workflow for the first time. In this post, we take a detailed look at the agreement's IP provisions, the specific regulations slated for repeal, the treaty accession timeline, and, most critically, the strategic implications for patent prosecution and portfolio management worldwide.

The Background: Why Argentina's IP Regime Has Been a Persistent Pain Point

To appreciate the magnitude of the ARTI's IP commitments, it helps to understand the regulatory landscape that practitioners have been navigating, and struggling with, for years.

Argentina has been a fixture on the USTR's Special 301 Priority Watch List since 1996, a designation reflecting persistent and significant concerns about IP protection and enforcement. The country's challenges in this area have been well-documented across multiple stakeholder submissions and annual reports, but several issues stand out as particularly consequential for patent holders.

Non-membership in the PCT. Argentina remains one of a small handful of commercially significant nations that have not joined the PCT system. Along with Venezuela and Pakistan, it represents a conspicuous gap in the treaty's otherwise near-universal coverage of 158 contracting states. For applicants, this has meant that Argentina cannot be designated in a PCT international application and cannot serve as a national phase entry point. Instead, practitioners seeking Argentine patent protection must file a direct national application under the Paris Convention within the 12-month priority period, a window that does not benefit from the extended 30-month timeline available for PCT national phase entries. The practical consequence is that Argentina must be identified as a filing target very early in the portfolio decision-making process, well before the PCT system provides the deferred decision-making flexibility that most applicants rely on for other jurisdictions. Applicants who wait until the typical 30-month PCT decision point to consider Argentina will find that their priority window has long since closed. Moreover, because a published PCT application constitutes prior art in Argentina upon publication, and Argentina has no "secret prior art" provisions, an applicant who files a PCT application without simultaneously filing in Argentina risks having their own published PCT application used as prior art against a later-filed Argentine application. This has caught more than a few applicants off guard.

Restrictive patentability guidelines for pharmaceuticals. In May 2012, Argentina's Ministry of Industry, Ministry of Health, and the National Institute of Industrial Property (INPI) jointly issued Resolutions No. 118/2012, 546/2012, and 107/2012 (collectively, the "Pharmaceutical Guidelines"). These regulations established examination criteria that went well beyond the standard novelty, inventive step, and industrial applicability requirements of Argentina's Patent Law No. 24,481 and the TRIPS Agreement. Under the Pharmaceutical Guidelines, many of the most common categories of pharmaceutical inventions, including compositions, dosages, salts, esters and ethers, polymorphs, analogous processes, active metabolites and pro-drugs, enantiomers, and selection patents, were effectively declared non-patentable subject matter as a general rule. New formulations and their methods of preparation were presumed obvious. The scope and efficacy of Markush-type claims were severely restricted. The result was a regime that made obtaining meaningful patent protection for pharmaceutical innovations in Argentina exceptionally difficult, even for inventions that would be routinely patented in the United States, Europe, Japan, and most other major jurisdictions. Multiple stakeholder groups, including the American Chamber of Commerce in Argentina and industry coalitions, have argued that these guidelines violated Article 27.1 of the TRIPS Agreement, which requires patent protection for inventions in all fields of technology. A lawsuit seeking to abrogate the Pharmaceutical Guidelines was filed in Argentine federal courts in June 2012, and remained pending for over a decade without resolution.

Restrictive patentability guidelines for biotechnology. In September 2015, INPI issued Resolution No. 283/2015 (the "Biotech Regulation"), which imposed additional patentability restrictions on biotechnological inventions involving plants and animals. The Biotech Regulation narrowed the patentability of inventions based on nucleotide or amino acid sequences, expanded the category of non-patentable subject matter to include genetically modified organelles, and imposed patentability criteria beyond those required by the TRIPS Agreement. The combined effect of the Pharmaceutical Guidelines and the Biotech Regulation was to create a uniquely restrictive environment for exactly the types of inventions that pharmaceutical and biotechnology companies most need to protect.

Severe patent backlog and prosecution delays. Argentina's patent prosecution timeline has been a longstanding concern. Average pendency for pharmaceutical and biotechnology applications has ranged from 5 to 8 years from filing to grant. Argentina lacks any patent term adjustment mechanism to compensate for administrative delays, meaning that applicants who eventually receive a grant may find that a substantial portion of their patent term has been consumed by prosecution.

Absence of regulatory data protection. Argentina has not implemented effective, time-limited exclusivity protections for undisclosed test data submitted for marketing authorization of pharmaceutical and agricultural chemical products, a persistent concern under TRIPS Article 39.3.

This landscape, the combination of PCT non-membership, restrictive patentability standards, crushing delays, and weak data protection, has made Argentina one of the most challenging major-market jurisdictions for pharmaceutical and biotech patent holders. The ARTI addresses virtually all of these issues.

The ARTI's IP Architecture: Three Strategic Pillars

The agreement's IP provisions can be understood as resting on three interconnected pillars: treaty accession, regulatory reform, and enforcement modernization. Each deserves detailed examination.

Pillar One: Accession to International IP Treaties

The centerpiece of the ARTI's IP chapter is Argentina's commitment to accede to a series of foundational international treaties. The timeline is aggressive:

By April 30, 2026, Argentina must submit the Patent Cooperation Treaty (PCT) to Congress for consideration and a vote on ratification. This is the most immediately consequential commitment in the agreement. PCT accession would bring Argentina into the international patent filing system that covers virtually every other commercially significant jurisdiction in the world, fundamentally changing how applicants manage Argentine filings within their global portfolios.

By the end of 2027, Argentina must submit to Congress for consideration and a vote on ratification: the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (1977); the Patent Law Treaty (2000); the Geneva Act of the Hague Agreement Concerning the International Registration of Industrial Designs (1999); the International Convention for the Protection of New Varieties of Plants — UPOV 1991 Act; the Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks (1989); the Singapore Treaty on the Law of Trademarks (2006), and the Brussels Convention Relating to the Distribution of Programme-Carrying Signals Transmitted by Satellite (1974) .

The significance of this treaty accession program cannot be overstated. It represents Argentina's most comprehensive commitment to integration with the international IP system in the country's history. For patent practitioners specifically, the PCT and Budapest Treaty accessions are transformative.

PCT accession would mean that, for the first time, applicants could designate Argentina in a PCT international application and enter the Argentine national phase at the 30-month mark (or potentially 31 months, depending on Argentina's implementing legislation). This would eliminate the current requirement to make a filing decision for Argentina within the 12-month Paris Convention window, a constraint that has forced premature and sometimes costly decisions. It would also bring Argentina within the scope of international search and preliminary examination reports, potentially improving prosecution efficiency before INPI.

Argentina currently accepts deposits made in recognized International Depositary Authorities (IDAs), however, the country is not formally a party member to the Budapest treaty, i.e., Argentina is not internationally bound by the system. Therefore, this commitment is aimed at aligning with international standards, considering that Budapest Treaty accession allows applicants to satisfy biological material deposit requirements for Argentine patent applications through recognized institutions worldwide. For biotechnology applicants, this is a meaningful practical improvement.

Pillar Two: Repeal of Restrictive Patentability Regulations

The ARTI requires Argentina to repeal the regulations that have constrained chemical, pharmaceutical and biotechnology patentability for over a decade. Specifically:

Joint Resolutions No. 118/2012, No. 546/2012, and No. 107/2012, the Pharmaceutical Guidelines, are to be repealed. This would remove the blanket presumptions of non-patentability and obviousness that have been applied to compositions, dosages, salts, polymorphs, enantiomers, selection patents, and other standard pharmaceutical inventions. It would also lift the severe restrictions on Markush-type claims.

Resolution No. 283/2015, the Biotech Regulation, is also to be repealed. This would eliminate the additional patentability barriers applied to biotechnological inventions involving nucleotide sequences, amino acid sequences, and genetically modified organelles.

The expected effect is that pending applications, including those that may have been rejected or narrowed under the restrictive criteria, would no longer be examined under the superseded guidelines. Examination practices would shift toward internationally accepted standards, aligning Argentina more closely with the approaches taken by the USPTO, EPO, and JPO.

This is a development of enormous practical consequence. For years, applicants filing in Argentina have had to draft claims specifically tailored to the Pharmaceutical Guidelines' narrow requirements, often filing claim sets that bore little resemblance to those prosecuted in parallel before other major offices. The repeal of these regulations should allow applicants to pursue broader claim coverage in Argentina, more consistent with their global claim strategy.

Pillar Three: Enforcement Modernization and Additional Reforms

The ARTI's IP provisions extend well beyond patents to encompass a broader enforcement modernization agenda. Key elements include the introduction of criminal sanctions with deterrent effect for IP infringement; expanded powers for customs authorities including ex officio actions against  infringing goods in transit; strengthened penalties for counterfeiting activities linked to organized crime; and enhanced enforcement efforts against piracy and counterfeiting, including in digital environments; cooperation frameworks between ISPs, rights holders, and enforcement bodies to address online piracy; publication of periodic enforcement statistics. The agreement also contemplates measures aimed at reducing patent examination backlogs and improving prosecution timelines, particularly in sectors such as pharmaceuticals and biotechnology.

The agreement also addresses regulatory data protection, with Argentina committing to analyze the feasibility of implementing a data protection regime consistent with the standards established under the United States–Mexico–Canada Agreement (USMCA). While this falls short of a binding commitment to implement USMCA-style data exclusivity, it opens a pathway for regulatory data protection that has been absent from Argentina's framework.

With respect to geographical indications, the ARTI requires Argentina to maintain transparent and fair procedures for the recognition of GIs, including opposition and cancellation mechanisms. The agreement emphasizes the protection of prior trademark rights over subsequently registered geographical indications and requires that terms recognized as GIs must genuinely possess a quality, reputation, or other characteristic attributable to their geographic origin.

Strategic Implications for Patent Practitioners

The ARTI's IP provisions create both opportunities and action items for patent practitioners and portfolio managers. Here is where we turn from describing the agreement to advising on what to do about it.

Reassess the Argentina filing decision framework. For applicants who have routinely excluded Argentina from their global filing strategies, whether due to the compressed Paris Convention timeline, the restrictive patentability standards, or both, the ARTI demands a fresh assessment. If Argentina accedes to the PCT and repeals its restrictive examination guidelines, the cost-benefit analysis for Argentine patent protection shifts materially. Argentina's market size, growing pharmaceutical sector, and position as a regional economic anchor make it a jurisdiction that warrants inclusion in many more portfolios than currently consider it. Practitioners should begin identifying clients and technology areas where Argentine patent protection would add strategic value, particularly in pharmaceuticals, biologics, gene therapy, and biotechnology, the sectors most directly affected by the regulatory reforms.

Monitor the PCT ratification timeline closely. The April 30, 2026, deadline for submission to Congress is not the same as ratification, let alone entry into force. Congressional deliberation, implementing legislation, and WIPO administrative processes will add additional time. Practitioners should track not only the congressional submission but the subsequent legislative and regulatory steps required for PCT entry into force. The precise national phase entry deadline (30 or 31 months), translation requirements, and fee structures that Argentina adopts will be critical details for filing workflows.

Review pending Argentine applications. Applicants with pending patent applications in Argentina, particularly those that have been narrowed, rejected, or stalled under the Pharmaceutical Guidelines or the Biotech Regulation, should assess whether the repeal of those regulations creates an opportunity to amend claims, request reconsideration, or otherwise pursue broader protection. The transition from the restrictive guidelines to international standards may create a window for re-engaging with applications that were previously considered non-viable.

Align claim drafting strategy. Under the current regime, applicants often filed Argentina-specific claim sets that differed substantially from those used in other jurisdictions. With the anticipated repeal of the restrictive guidelines, there is an opportunity, and a strategic incentive, to align Argentine claim drafting more closely with global claim strategy. This may mean preparing broader claim sets for new filings and revisiting the claim strategy for applications still in prosecution.

Plan for the transition period. The timeline between the signing of the agreement and the full implementation of its IP provisions will be a period of significant uncertainty. How will INPI handle applications that are currently under examination? Will the repeal of the guidelines apply retroactively to pending applications, or only prospectively to new filings? Will INPI issue new examination guidelines to replace those being repealed? Practitioners should maintain close contact with experienced Argentine patent counsel to navigate these transitional questions.

Consider the broader treaty accession agenda. The Budapest Treaty and Patent Law Treaty accessions (targeted for congressional submission by end of 2027) have practical implications for filing strategy. Budapest Treaty accession will simplify biological material deposit compliance. The Patent Law Treaty will harmonize formal requirements and provide standardized relief mechanisms for missed deadlines, a particularly valuable safeguard given Argentina's historically challenging procedural environment. Practitioners with design portfolios should note the Hague Agreement accession, which will bring Argentina into the international design registration system.

Factor in the enforcement improvements. For clients making commercialization decisions in Argentina, the enforcement reforms contemplated under the ARTI framework, including stronger criminal sanctions for IP infringement, expanded ex officio powers for customs authorities, and enhanced measures to address piracy and counterfeiting in digital environments, are relevant to the broader IP risk assessment. Enhanced enforcement may increase the value of patent rights, which in turn supports the investment case for seeking Argentine patent protection.

A Comparative Perspective: Argentina in the Global Context

The ARTI's IP provisions are best understood not in isolation but as part of a broader trend of emerging-market IP modernization that Patent Panorama has been tracking across jurisdictions. Argentina's commitment to PCT accession, for example, mirrors the trajectory that many countries have followed as they seek to integrate more fully into the global innovation economy. The simultaneous repeal of restrictive patentability guidelines and commitment to stronger enforcement aligns with the pattern we have seen in other jurisdictions moving off the Special 301 Priority Watch List, though Argentina's reforms are notably more comprehensive than most.

Readers who have followed our coverage of patent prosecution developments across Latin America will recognize familiar themes: the tension between public health policy objectives and international IP commitments, the challenge of reducing patent backlogs while maintaining examination quality, and the role of bilateral trade agreements in catalyzing IP reform. What distinguishes the ARTI is the breadth and specificity of its commitments, the aggressive timelines, and the fact that it addresses virtually every major concern that stakeholders and trading partners have raised about Argentina's IP regime for the past three decades.

It is also worth noting that the agreement comes at a moment of broader realignment in Argentina's economic and trade policy. The current administration has signaled a willingness to pursue market-oriented reforms and closer integration with international standards across multiple policy domains, and the ARTI's IP provisions are consistent with that trajectory.

What Remains Uncertain

Significant uncertainties remain. The ARTI establishes commitments and timelines, but implementation will depend on Argentine congressional action, regulatory execution, and institutional capacity at INPI.

The PCT submission deadline of April 30, 2026, is less than two months away. Whether Congress will act quickly on ratification, or whether the process will extend through protracted legislative deliberation, remains to be seen. Historical experience in Argentina and other jurisdictions suggests that the path from submission to entry into force can be measured in months or years, not weeks.

The repeal of the Pharmaceutical Guidelines and Biotech Regulation, while clearly mandated by the agreement, will require either executive or legislative action, followed by the development of replacement examination guidance. The transition from one examination framework to another invariably creates a period of unpredictability.

INPI's capacity to implement these reforms, given the backdrop of innumerable pending applications and chronically constrained resources, is a legitimate concern. Reducing patent pendency while simultaneously overhauling examination standards is an immensely challenging institutional undertaking.

And while the agreement contemplates patent term extensions to compensate for unreasonable delays, the commitment at this stage is limited to evaluating the legal feasibility of such a mechanism, not to implementing one. Practitioners should not yet assume that Argentina will adopt a patent term adjustment system comparable to those available in the United States or other jurisdictions.

Key Takeaways

The U.S.–Argentina Agreement on Reciprocal Trade and Investment represents a watershed moment for intellectual property protection in Argentina. For patent practitioners and portfolio managers, the essential action items are:

Track the April 30, 2026, PCT congressional submission deadline and the subsequent ratification and implementation process. Begin planning now for how PCT accession will integrate into global filing workflows.

Reassess whether Argentina should be included, or restored, in global patent filing strategies, particularly for pharmaceutical, biotechnology, and chemical inventions that were previously impractical to protect under the restrictive guidelines.

Review pending Argentine applications for opportunities to broaden claims or reopen prosecution in light of the anticipated repeal of Joint Resolutions No. 118/2012, 546/2012, and 107/2012 and Resolution No. 283/2015.

Align Argentine claim drafting with global claim strategy in anticipation of examination standards that more closely conform to international norms.

Monitor the 2027 treaty accession deadlines for the Budapest Treaty, Patent Law Treaty, Hague Agreement, Madrid Protocol, UPOV 1991, and Singapore Treaty, each of which carries distinct portfolio management implications.

Engage experienced Argentine patent counsel to navigate the transition period and to monitor INPI's implementation of new examination practices.

The ARTI does not guarantee that all these reforms will be implemented on schedule or in the precise form that practitioners might hope for. But the direction and specificity of the commitments are unmistakable. Argentina is moving, rapidly and deliberately, toward integration with the international IP system. The practitioners and businesses that prepare now, rather than waiting for the legislative process to conclude, will be best positioned to capitalize on what may be the most significant opening in Argentine patent strategy in a generation.

This post was written by Lisa Mueller and Maria Soledad Prado and Veronica Kapovik from Clarke Modet.